RLMD Relmada Therapeutics Inc

Price (delayed)

$3.81

Market cap

$114.96M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.12

Enterprise value

$113.63M

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Its experienced and dedicated team is committed ...

Highlights
The EPS has grown by 35% YoY and by 4.9% from the previous quarter
Relmada Therapeutics's net income has increased by 34% YoY and by 4.5% QoQ
The quick ratio has contracted by 48% YoY and by 14% from the previous quarter
RLMD's equity is down by 43% YoY and by 16% from the previous quarter

Key stats

What are the main financial stats of RLMD
Market
Shares outstanding
30.17M
Market cap
$114.96M
Enterprise value
$113.63M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.6
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$94.3M
EBITDA
-$94.3M
Free cash flow
-$48.19M
Per share
EPS
-$3.12
Free cash flow per share
-$1.6
Book value per share
$2.39
Revenue per share
$0
TBVPS
$2.8
Balance sheet
Total assets
$84.41M
Total liabilities
$12.36M
Debt
$0
Equity
$72.05M
Working capital
$72M
Liquidity
Debt to equity
0
Current ratio
6.82
Quick ratio
6.76
Net debt/EBITDA
0.01
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-91.3%
Return on equity
-102.1%
Return on invested capital
-110%
Return on capital employed
-130.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RLMD stock price

How has the Relmada Therapeutics stock price performed over time
Intraday
-6.16%
1 week
19.44%
1 month
26.58%
1 year
34.15%
YTD
-7.97%
QTD
27%

Financial performance

How have Relmada Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$98.54M
Net income
-$94.3M
Gross margin
N/A
Net margin
N/A
Relmada Therapeutics's operating income has increased by 35% YoY and by 5% from the previous quarter
Relmada Therapeutics's net income has increased by 34% YoY and by 4.5% QoQ

Growth

What is Relmada Therapeutics's growth rate over time

Valuation

What is Relmada Therapeutics stock price valuation
P/E
N/A
P/B
1.6
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 35% YoY and by 4.9% from the previous quarter
The P/B is 60% less than the 5-year quarterly average of 4.2 but 42% more than the last 4 quarters average of 1.2
RLMD's equity is down by 43% YoY and by 16% from the previous quarter

Efficiency

How efficient is Relmada Therapeutics business performance
Relmada Therapeutics's return on equity has decreased by 12% YoY and by 9% QoQ
The ROA has declined by 10% year-on-year and by 7% since the previous quarter
RLMD's return on invested capital is down by 2.6% since the previous quarter

Dividends

What is RLMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RLMD.

Financial health

How did Relmada Therapeutics financials performed over time
The company's current ratio fell by 49% YoY and by 15% QoQ
The quick ratio has contracted by 48% YoY and by 14% from the previous quarter
RLMD's debt is 100% smaller than its equity
RLMD's equity is down by 43% YoY and by 16% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.